Evidence map›Paper›PMID 40760357›Full record

SynthesisAdvances in therapy2025

Global Incidence and Mortality of Myocardial Infarction in Multi-Modality Head and Neck Cancer Treatment: A Systematic Review and Meta-analysis.

Ameya A Asarkar, Srivatsa Surya Vasudevan, Veronica Fernandez-Alvarez, Jan B Vermorken, Fernando López Álvarez, Karthik N Rao, Nabil F Saba, Remco de Bree, Carlos Suárez, Avraham Eisbruch and 3 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ameya A AsarkarDepartment of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA. ameya.asarkar@lsuhs.edu.ORCID http://orcid.org/0000-0001-9028-8746
Srivatsa Surya VasudevanDepartment of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA.
Veronica Fernandez-AlvarezDepartment of Vascular and Endovascular Surgery, Hospital Universitario Central de Asturias, Oviedo, Spain.
Jan B VermorkenDepartment of Medical Oncology, Antwerp University Hospital, Edegem, Belgium.
Fernando López ÁlvarezDepartment of Otolaryngology-Head and Neck Surgery, Hospital Universitario Central de Asturias, University of Oviedo, ISPA, IUOPA, CIBERONC. Oviedo, Spain, Oviedo, Spain.
Karthik N RaoDepartment of Head and Neck Oncology, Sri Shankara Cancer Foundation, Bangalore, India.
Nabil F SabaDepartment of Hematology and Medical Oncology, The Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Remco de BreeDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Carlos SuárezUniversidad de Oviedo, Oviedo, Spain.
Avraham EisbruchDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Sandra NuytsLaboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, Leuven, Belgium.
Carol BradfordDepartment of Otolaryngology-Head and Neck Surgery, The Ohio State University College of Medicine, Columbus, OH, USA.
Alfio FerlitoCoordinator of the International Head and Neck Scientific Group, Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMyocardial infarction (MI) incidence and mortality vary following multi-modality treatment for head and neck cancer (HNC). This systematic review and meta-analysis evaluate these rates.

methodsWe searched PubMed, Embase, ScienceDirect, and Web of Science (inception to March 2025) for studies reporting MI incidence or mortality after HNC treatment. A random-effects meta-analysis yielded pooled proportions. Subgroup analyses examined variations by treatment modality, time period (pre-/post-2010), and geography.

resultsOf 680 studies, 53 were included, encompassing 85,948 patients with HNC. The global pooled MI incidence was 1.7% (95% CI 1.2-2.3%), decreasing from 2.6% (pre-2010) to 1.5% (post-2010). Incidence was lowest with upfront surgery alone (1.2%) and higher with surgery plus adjuvant therapy (2.7%), primary chemoradiotherapy (CRT) (2.3%), radiotherapy (RT) alone (2.4%), or chemotherapy (CT) alone (2.1%). Global pooled MI mortality was 42.1% (95% CI 15.3-74.6%), declining from 49.8% (pre-2010) to 36.0% (post-2010). Male sex (p = 0.01) and longer follow-up in the RT group (p = 0.01) were associated with higher MI incidence via meta-regression; longer follow-up was also linked to higher mortality (p = 0.028).

conclusionThis systematic review (PROSPERO: CRD420251040579) estimated the global MI incidence post-HNC treatment to be 1.7%, with the lowest after surgery alone and no significant geographic variation. MI mortality is high (42.1%) but has decreased over time. These findings demonstrate significant cardiovascular burden associated with HNC treatment, particularly non-surgical modalities, highlighting the need for targeted cardiovascular surveillance strategies.

Indexed as

Head and Neck NeoplasmsMyocardial InfarctionCombined Modality TherapyFemaleHumansIncidenceMaleCombined modality therapyHead and neck cancerIncidenceMortalityMyocardial infarctionMyocardial infarction incidence

Identifiers

PMID40760357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.